EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)Klinische Studie (Phase III)Open Access · CC BY-NC-ND 4.0

Sustained Therapeutic Efficacy of Intravenous Plasminogen Concentrate in Pediatric Patients With Type 1 Plasminogen Deficiency: An Analysis of Dosing Parameters and Clinical Outcomes

Charles Nakar, Karen Thibaudeau, Mary Mathias iD, Heather McDaniel, Madlen Reschke, Klaus Tenbrock, Joseph M Parker, Amy Shapiro

Pediatric Blood & Cancer · 2026

DOI: 10.1002/1545-5017.70454 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift Pediatric Blood & Cancer, 2026. Verfasst von Charles Nakar und 7 weiteren Autor:innen. Beteiligte Einrichtung: Indiana Hemophilia and Thrombosis Center Inc., Indianapolis, Indiana, USA. Hauptthemen laut MEDLINE: Plasminogen, Blood Coagulation Disorders, Inherited. Die Arbeit nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Kedrion Biopharma Inc..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Type 1 plasminogen deficiency (PLGD‐1) is an ultra‐rare autosomal recessive disorder caused by variants in the PLG gene and affects approximately 1.6 individuals per million. The condition is characterized by decreased plasminogen levels and impaired function, resulting in fibrin‐rich lesions on mucous membranes throughout the body. Pediatric patients often experience earlier symptoms than adults, including more severe life‐threatening complications such as airway obstruction and hydrocephalus. Procedure This analysis describes 17 pediatric patients (ages 11 months to 16 years) with PLGD‐1 treated with intravenous (IV) plasminogen concentrate enrolled in the Phase 2/3 pivotal trial (NCT02690714), long‐term study (NCT03642691), and expanded access and compassionate use programs of IV plasminogen concentrate at a dose of 6.6 mg/kg at intervals ranging from daily to once every 35 days.

Results

Baseline plasminogen activity ranged from

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PlasminogenBlood Coagulation Disorders, InheritedHumansChildChild, PreschoolAdolescentFemaleMaleInfantConjunctivitisSkin Diseases, Genetic

Stichwörter der Autor:innen

Type 1 plasminogen deficiencyfibrin‐rich lesionshypoplasminogenemialesion resolutionpediatric patientsplasminogen pharmacokinetic profile

Substanzen

Plasminogen

Autor:innen und Institutionen

  • Indiana Hemophilia and Thrombosis Center Inc., Indianapolis, Indiana, USA.
  • Prometic Bioproduction Inc. (doing business as Kedrion Biopharma Canada), Laval, Quebec, Canada.
  • Great Ormond Street Hospital for Children NHS, London, UK.
  • Vanderbilt University Medical Center, Nashville, Tennessee, USA.
  • Charité - University Medicine, Berlin, Germany.
  • RWTH Aachen, Aachen, Germany.

ORCID-Profile: Mary Mathias

Förderung

  • Kedrion Biopharma Inc.

Zitieren

APA

Nakar, C., Thibaudeau, K., Mathias, M., McDaniel, H., Reschke, M., Tenbrock, K., Parker, J. M., & Shapiro, A. (2026). Sustained Therapeutic Efficacy of Intravenous Plasminogen Concentrate in Pediatric Patients With Type 1 Plasminogen Deficiency: An Analysis of Dosing Parameters and Clinical Outcomes. Pediatric Blood & Cancer. https://doi.org/10.1002/1545-5017.70454

Vancouver

Nakar C, Thibaudeau K, Mathias M, McDaniel H, Reschke M, Tenbrock K, et al. Sustained Therapeutic Efficacy of Intravenous Plasminogen Concentrate in Pediatric Patients With Type 1 Plasminogen Deficiency: An Analysis of Dosing Parameters and Clinical Outcomes. Pediatric Blood & Cancer. 2026. doi:10.1002/1545-5017.70454

BibTeX
@article{Nakar2026,
  author = {Nakar, Charles and Thibaudeau, Karen and Mathias, Mary and McDaniel, Heather and Reschke, Madlen and Tenbrock, Klaus and Parker, Joseph M and Shapiro, Amy},
  title = {Sustained Therapeutic Efficacy of Intravenous Plasminogen Concentrate in Pediatric Patients With Type 1 Plasminogen Deficiency: An Analysis of Dosing Parameters and Clinical Outcomes},
  journal = {Pediatric Blood & Cancer},
  year = {2026},
  doi = {10.1002/1545-5017.70454}
}
Kostenlos starten →